Analyst Ratings for [ABCL] AbCellera Biologics Inc

8/20/24	Downgrades	Buy Hold	X
ABCL AbCellera Biologics The Benchmark Company
2/22/24	Upgrades	Hold Buy	X
ABCL AbCellera Biologics The Benchmark Company
$9
12/5/23	Initiated	Overweight	X
ABCL AbCellera Biologics KeyBanc Capital Markets
$6
11/6/23	Downgrades	Buy Hold	X
ABCL AbCellera Biologics The Benchmark Company
2/28/23	Initiated	Outperform	X
ABCL AbCellera Biologics Cowen
12/15/22	Initiated	Buy	X
ABCL AbCellera Biologics Goldman
$30
11/16/22	Initiated	Buy	X
ABCL AbCellera Biologics Truist
$29
12/21/21	Initiated	Buy	X
ABCL AbCellera Biologics The Benchmark Company
$27
11/19/21	Initiated	Overweight	X
ABCL AbCellera Biologics Piper Sandler
$33
1/5/21	Initiated	Buy	X
ABCL AbCellera Biologics Berenberg
$53
1/5/21	Initiated	Outperform	X
ABCL AbCellera Biologics BMO Capital Markets
$48
1/5/21	Initiated	Outperform	X
ABCL AbCellera Biologics Credit Suisse
$52
1/5/21	Initiated	Buy	X
ABCL AbCellera Biologics Stifel
$59
1/5/21	Initiated	Outperform	X
ABCL AbCellera Biologics SVB Leerink
$45

ABCL AbCellera Biologics Inc

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company also develops next-generation transgenic mice that provide a source of fully-human antibodies for the discovery of therapeutic antibody candidates. It has a discovery partnership agreement with Eli Lilly and Company for the discovery of various targets. AbCellera Biologics Inc. was founded in 2012 and is headquartered in Vancouver, Canada.